RENALYTIX PLC

• ⚠

  Material uncertainty over going concern

  We draw attention to note 3 in the financial statements, which indicates that the group has incurred a net loss of $20.4m during the year ended 30 June 2025. As stated in note 3, these events or conditions, along with the other matters as set forth in note 3, indicate that a material uncertainty exists that may cast significant doubt on the group's ability to continue as a going concern. Our opinion is not modified in respect of this matter.

1. RENALYTIX PLC 2021-06-23 → present
2. RENALYTIX AI PLC 2018-03-15 → 2021-06-23

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

PKF Littlejohn LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“We draw attention to note 3 in the financial statements, which indicates that the group has incurred a net loss of $20.4m during the year ended 30 June 2025. As stated in note 3, these events or conditions, along with the other matters as set forth in note 3, indicate that a material uncertainty exists that may cast significant doubt on the group's ability to continue as a going concern. Our opinion is not modified in respect of this matter.”

Group structure

1. RENALYTIX PLC · parent
   1. Renalytix AI, Inc. 100% · United States of America · Developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease
   2. Renalytix AI Limited 100% · Republic of Ireland · Developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease

Significant events

• “In July 2025, Renalytix announced an agreement with MVP Health Care, a U.S.-based insurer covering more than 700,000 patients.”
• “In September 2025, Renalytix signed an agreement with Tempus AI, Inc. ("Tempus") for integrated advanced diagnostic testing.”
• “In October 2024, the Company successfully renegotiated its long-term debt and settled key creditor balances.”
• “An additional $4 million of convertible debt was converted to equity, reducing outstanding long-term debt to £3.1m as of October 2025.”
• “Two oversubscribed capital raises occurred: £11.8m in October 2024 and £6.7m in September 2025.”
• “The Company delisted from NASDAQ and requalified as a foreign private issuer, saving over $1m a year in audit, insurance and other listing related fees.”
• “No cash bonus incentive was paid for FY2025, but stock options were issued with vesting based on revenue performance, share price performance, and time vested.”
• “Accelerated commercial launch/deployment of FDA approved, KDIGO guidelines recommended and Medicare re-imbursed kidneyintelX.dkd test in Q1-FY25.”
• “Partnership with MVP Health Care (August 2025): kidneyintelX.dkd testing to be made available across MVP's 770,000 members in New York and Vermont.”
• “Joslin Diabetes Center collaboration (August 2025): Multi-year agreement to utilize KidneyIntelX proteomics technology in pharma-sponsored drug development studies targeting CKD in diabetes.”
• “Tempus AI collaboration (September 2025): Strategic partnership to integrate KidneyIntelX testing into Tempus' precision medicine platform.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

11

last 12 months

Capital events

5

last 24 months

Officers appointed

1

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +30.4%

  £1,704,967 → £2,223,870

• Cash

  -23.4%

  £3,484,062 → £2,668,643

• Net assets

  +22.2%

  -£6,671,609 → -£5,189,029

• Employees

  -26.7%

  60 → 44

• Operating profit

  +43.6%

  -£22,609,340 → -£12,750,185

• Profit before tax

  +52.1%

  -£33,728,688 → -£16,160,119

• Wages

  -13%

  £5,707,932 → £4,966,642

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers